Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab. Objective: Aim of this study w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2020-09-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2140 |
| _version_ | 1828846772792852480 |
|---|---|
| author | Roberto Ravasio Roberto Giacomelli Stefano Bianchi |
| author_facet | Roberto Ravasio Roberto Giacomelli Stefano Bianchi |
| author_sort | Roberto Ravasio |
| collection | DOAJ |
| description | Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab.
Objective: Aim of this study was to estimate the budget impact of the use of anakinra compared to canakinumab and tocilizumab in the treatment of patients with AOSD or SJIA.
Methods: Considering the perspective of the Italian National Health Service (iNHS), a budget impact model (BIM) was developed to estimate the drugs costs of anakinra, canakinumab and tocilizumab up to 12 months. The BIM showed the difference of drug expenditure generated by the base case calculated for current prescription volumes, and for different prescription volume scenarios with increased anakinra prescription. Key variables were tested in the sensitivity analysis.
Results: Compared to the current scenario for SJIA, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€1,118,005 [-12.7%] or -€2,054,502 [-23.4%]). Compared to the current scenario for AOSD, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€4,024,585 [-13.5%] or -€8,049,169 [-27.0%]).
Conclusion: According to the present analysis, the use of anakinra, as an alternative to canakinumab or tocilizumab in patients with AOSD or SJIA, could represent a cost-saving option for the iNHS. |
| first_indexed | 2024-12-12T21:55:19Z |
| format | Article |
| id | doaj.art-5cb1cb25ac5d47a08f9d4d37c19b6e4d |
| institution | Directory Open Access Journal |
| issn | 2284-2403 2283-5733 |
| language | English |
| last_indexed | 2024-12-12T21:55:19Z |
| publishDate | 2020-09-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj.art-5cb1cb25ac5d47a08f9d4d37c19b6e4d2022-12-22T00:10:40ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332020-09-017110.33393/grhta.2020.2140Budget Impact Analysis of anakinra in the treatment of patients with Still’s DiseaseRoberto Ravasio0Roberto Giacomelli1Stefano Bianchi2Health Publishing & Services S.r.l., Milan - ItalyDepartment of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L’Aquila, L’Aquila - ItalyUnità Operativa Servizio farmaceutico ospedaliero e territoriale Azienda Usl Ferrara - ItalyBackground: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab. Objective: Aim of this study was to estimate the budget impact of the use of anakinra compared to canakinumab and tocilizumab in the treatment of patients with AOSD or SJIA. Methods: Considering the perspective of the Italian National Health Service (iNHS), a budget impact model (BIM) was developed to estimate the drugs costs of anakinra, canakinumab and tocilizumab up to 12 months. The BIM showed the difference of drug expenditure generated by the base case calculated for current prescription volumes, and for different prescription volume scenarios with increased anakinra prescription. Key variables were tested in the sensitivity analysis. Results: Compared to the current scenario for SJIA, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€1,118,005 [-12.7%] or -€2,054,502 [-23.4%]). Compared to the current scenario for AOSD, an increase in the market share of anakinra (40% or 50%) would lead to a reduction in the drug expenditure sustained by iNHS (-€4,024,585 [-13.5%] or -€8,049,169 [-27.0%]). Conclusion: According to the present analysis, the use of anakinra, as an alternative to canakinumab or tocilizumab in patients with AOSD or SJIA, could represent a cost-saving option for the iNHS.https://journals.aboutscience.eu/index.php/grhta/article/view/2140Adult onset Still’s diseaseAnakinraBudget impactItalian National Health ServiceStill’s diseaseSystemic juvenile idiopathic arthritis |
| spellingShingle | Roberto Ravasio Roberto Giacomelli Stefano Bianchi Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease Global & Regional Health Technology Assessment Adult onset Still’s disease Anakinra Budget impact Italian National Health Service Still’s disease Systemic juvenile idiopathic arthritis |
| title | Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease |
| title_full | Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease |
| title_fullStr | Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease |
| title_full_unstemmed | Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease |
| title_short | Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease |
| title_sort | budget impact analysis of anakinra in the treatment of patients with still s disease |
| topic | Adult onset Still’s disease Anakinra Budget impact Italian National Health Service Still’s disease Systemic juvenile idiopathic arthritis |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/2140 |
| work_keys_str_mv | AT robertoravasio budgetimpactanalysisofanakinrainthetreatmentofpatientswithstillsdisease AT robertogiacomelli budgetimpactanalysisofanakinrainthetreatmentofpatientswithstillsdisease AT stefanobianchi budgetimpactanalysisofanakinrainthetreatmentofpatientswithstillsdisease |